BioWorld

May 24, 2007

Public Offering Generates $163M In Cash For Advanced Magnetics

Awaiting results from the final of four pivotal studies of its iron replacement therapeutic ferumoxytol, Cambridge, Mass.-based Advanced Magnetics Inc. is raising $162.9 million. (BioWorld Today) Read More

Cypress Shares Soar On Positive Phase III Data In Fibromyalgia

Vion Halts Phase III AML Trial, Causing Stock Drop

NewCo News: Arete Completes $51M Round For New Hypertension Class

Sirtris Increases Shares, Raises $60M In IPO For Sirtuin Work

Pivotal PolyHeme Trial Fails To Hit Endpoints, Hurting Northfield

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

In the clinic for June 12, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...